

SUMMARY

In one aspect the present disclosure refers to use of a compound in the manufacture of a medicament for treating a cutaneous, neutrophilic, inflammatory disease in a subject, wherein the compound is an inhibitor of C5a activity, and wherein the cutaneous, neutrophilic, inflammatory disease is selected from the group consisting of hidradenitis suppurativa (HS); PASH (PG, acne and hidradenitis suppurativa); PAPASH (pyogenic arthritis, acne, PG and hidradenitis suppurativa), wherein the inhibitor of C5a activity is IFX-1 antibody or antigen binding fragment thereof, comprising a variable heavy chain consisting in the following order of the amino acid sequences of FR1 of SEQ ID NO: 18, CDR1 of SEQ ID NO: 14, FR2 of SEQ ID NO: 19, CDR2 of SEQ ID NO: 10, FR3 of SEQ ID NO: 20, CDR3 of SEQ ID NO: 6 and FR4 of SEQ ID NO: 21 and a variable light chain consisting in the following order of the amino acid sequences of FR1 of SEQ ID NO: 22, CDR1 of SEQ ID NO: 16, FR2 of SEQ ID NO: 23, CDR2 of SEQ ID NO: 12, FR3 of SEQ ID NO: 24, CDR3 of SEQ ID NO: 8 and FR4 of SEQ ID NO: 25. In one example, there is disclosed compound for use in the treatment of a cutaneous, neutrophilic, inflammatory disease in a subject, wherein the compound is an inhibitor of C5a activity, and wherein the cutaneous, neutrophilic, inflammatory disease is selected from the group consisting of hidradenitis suppurativa (HS); Pyoderma gangrenosum (PG); PAPA (pyogenic arthritis, PG and acne); PASH (PG, acne and hidradenitis suppurativa); PAPASH (pyogenic arthritis, acne, PG and hidradenitis suppurativa); Sweet syndrome (SS); subcorneal pustular dermatosis (SPD); epidermolysis bullosa acquisita, erythema elevatum diutinum (EED); neutrophilic panniculitis; familial Mediterranean fever, cryopyrin-associated disorders, gout, and Schnitzler syndrome. In another example, there is disclosed a method for the treatment of a cutaneous, neutrophilic, inflammatory disease in a subject, comprising the step of administering to a subject in need thereof a therapeutic amount of a compound, wherein the compound is an inhibitor of C5a activity, and wherein the cutaneous, neutrophilic, inflammatory disease is selected from the group consisting of hidradenitis suppurativa (HS); Pyoderma gangrenosum (PG); PAPA (pyogenic arthritis, PG and acne); PASH (PG, acne and hidradenitis suppurativa); PAPASH (pyogenic arthritis, acne, PG and hidradenitis suppurativa); Sweet syndrome (SS); subcorneal pustular dermatosis (SPD); epidermolysis bullosa acquisita, erythema elevatum diutinum (EED); neutrophilic panniculitis; familial Mediterranean fever, cryopyrin-associated disorders, gout, and Schnitzler syndrome. In another example, there is disclosed a use of a compound for the preparation of a pharmaceutical composition for the treatment of a cutaneous, neutrophilic, inflammatory disease, wherein the compound is an inhibitor of C5a activity, and wherein the cutaneous, neutrophilic, inflammatory disease is selected from the group consisting of hidradenitis suppurativa (HS); Pyoderma gangrenosum (PG); PAPA (pyogenic arthritis, PG and acne); PASH (PG, acne and hidradenitis suppurativa); PAPASH (pyogenic arthritis, acne, PG and hidradenitis suppurativa); Sweet syndrome (SS); subcorneal pustular dermatosis (SPD); epidermolysis bullosa acquisita, erythema elevatum diutinum (EED); neutrophilic panniculitis; familial Mediterranean fever, cryopyrin-associated disorders, gout, and Schnitzler syndrome.

This summary of the invention does not necessarily describe all features of the present invention. Other embodiments will become apparent from a review of the ensuing detailed description.

Claims

1. Use of a compound in the manufacture of a medicament for treating a cutaneous,
5 neutrophilic, inflammatory disease in a subject, wherein the compound is an inhibitor of C5a activity, and
wherein the cutaneous, neutrophilic, inflammatory disease is selected from the group consisting of hidradenitis suppurativa (HS); PASH (PG, acne and hidradenitis suppurativa); PAPASH (pyogenic arthritis, acne, PG and hidradenitis suppurativa),
10 wherein the inhibitor of C5a activity
is IFX-1 antibody or antigen binding fragment thereof, comprising a variable heavy chain consisting in the following order of the amino acid sequences of FR1 of SEQ ID NO: 18, CDR1 of SEQ ID NO: 14, FR2 of SEQ ID NO: 19, CDR2 of SEQ ID NO: 10, FR3 of SEQ ID NO: 20, CDR3 of SEQ ID NO: 6 and FR4 of SEQ ID NO: 21 and a
15 variable light chain consisting in the following order of the amino acid sequences of FR1 of SEQ ID NO: 22, CDR1 of SEQ ID NO: 16, FR2 of SEQ ID NO: 23, CDR2 of SEQ ID NO: 12, FR3 of SEQ ID NO: 24, CDR3 of SEQ ID NO: 8 and FR4 of SEQ ID NO: 25.
2. The use of claim 1, wherein the compound is to be administered at a dose of 800 mg once
20 per week or at a dose of 800 mg twice per week.